优化ACS患者脂质管理的临床实践和途径的实施:重点关注8项欧洲倡议

4区 医学 Q1 Medicine
Marco Alings , Olivier Descamps , Benoit Guillon , Margret Leosdottir , Aldo P. Maggioni , Lluis Recasens , Walter S. Speidl , Rosario V. Tripodi , Ulf Landmesser , Alberico L. Catapano , Angela Pirillo
{"title":"优化ACS患者脂质管理的临床实践和途径的实施:重点关注8项欧洲倡议","authors":"Marco Alings ,&nbsp;Olivier Descamps ,&nbsp;Benoit Guillon ,&nbsp;Margret Leosdottir ,&nbsp;Aldo P. Maggioni ,&nbsp;Lluis Recasens ,&nbsp;Walter S. Speidl ,&nbsp;Rosario V. Tripodi ,&nbsp;Ulf Landmesser ,&nbsp;Alberico L. Catapano ,&nbsp;Angela Pirillo","doi":"10.1016/j.atherosclerosissup.2021.01.010","DOIUrl":null,"url":null,"abstract":"<div><p>Post-acute coronary syndrome (ACS) patients are at very high cardiovascular risk. Despite current guidelines strongly recommend to reduce LDL-C levels and initiation of high-intensity statins as early as possible in patients admitted with an ACS, less than half of ACS patients receive a high intensity statin, and a high percentage of has LDL-C well above the goal despite therapy. There are multiple reasons for that, including physician lack of guideline adherence, patient lack of compliance with treatment, and lack of standardized procedures. Furthermore, although the prevalence of familial hypercholesterolemia is higher among patients with ACS, this condition remains poorly estimated. To fill these gaps, some European countries have launched local initiatives for the in-hospital and post-discharge ACS patient lipid management. It appears that ensuring optimal therapy during hospitalization and dedicated follow-up protocols results in a significant improvement of lipid levels in these very high risk patients, which may translate into a reduced risk of recurrent future events.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e59-e64"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.010","citationCount":"5","resultStr":"{\"title\":\"Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives\",\"authors\":\"Marco Alings ,&nbsp;Olivier Descamps ,&nbsp;Benoit Guillon ,&nbsp;Margret Leosdottir ,&nbsp;Aldo P. Maggioni ,&nbsp;Lluis Recasens ,&nbsp;Walter S. Speidl ,&nbsp;Rosario V. Tripodi ,&nbsp;Ulf Landmesser ,&nbsp;Alberico L. Catapano ,&nbsp;Angela Pirillo\",\"doi\":\"10.1016/j.atherosclerosissup.2021.01.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Post-acute coronary syndrome (ACS) patients are at very high cardiovascular risk. Despite current guidelines strongly recommend to reduce LDL-C levels and initiation of high-intensity statins as early as possible in patients admitted with an ACS, less than half of ACS patients receive a high intensity statin, and a high percentage of has LDL-C well above the goal despite therapy. There are multiple reasons for that, including physician lack of guideline adherence, patient lack of compliance with treatment, and lack of standardized procedures. Furthermore, although the prevalence of familial hypercholesterolemia is higher among patients with ACS, this condition remains poorly estimated. To fill these gaps, some European countries have launched local initiatives for the in-hospital and post-discharge ACS patient lipid management. It appears that ensuring optimal therapy during hospitalization and dedicated follow-up protocols results in a significant improvement of lipid levels in these very high risk patients, which may translate into a reduced risk of recurrent future events.</p></div>\",\"PeriodicalId\":8592,\"journal\":{\"name\":\"Atherosclerosis. Supplements\",\"volume\":\"42 \",\"pages\":\"Pages e59-e64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.010\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atherosclerosis. Supplements\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S156756882100012X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis. Supplements","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S156756882100012X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5

摘要

急性冠脉综合征(ACS)后患者的心血管风险非常高。尽管目前的指南强烈建议ACS患者尽早降低LDL-C水平并开始高强度他汀类药物治疗,但只有不到一半的ACS患者接受了高强度他汀类药物治疗,而且有很高比例的ACS患者在接受治疗后LDL-C仍远高于目标。造成这种情况的原因有很多,包括医生不遵守指南,患者不遵守治疗,以及缺乏标准化的程序。此外,尽管家族性高胆固醇血症在ACS患者中的患病率较高,但这种情况仍未得到充分估计。为了填补这些空白,一些欧洲国家已经在当地发起了住院和出院后ACS患者脂质管理的倡议。似乎在住院期间确保最佳治疗和专门的随访方案可以显著改善这些高危患者的脂质水平,这可能转化为降低未来复发事件的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives

Post-acute coronary syndrome (ACS) patients are at very high cardiovascular risk. Despite current guidelines strongly recommend to reduce LDL-C levels and initiation of high-intensity statins as early as possible in patients admitted with an ACS, less than half of ACS patients receive a high intensity statin, and a high percentage of has LDL-C well above the goal despite therapy. There are multiple reasons for that, including physician lack of guideline adherence, patient lack of compliance with treatment, and lack of standardized procedures. Furthermore, although the prevalence of familial hypercholesterolemia is higher among patients with ACS, this condition remains poorly estimated. To fill these gaps, some European countries have launched local initiatives for the in-hospital and post-discharge ACS patient lipid management. It appears that ensuring optimal therapy during hospitalization and dedicated follow-up protocols results in a significant improvement of lipid levels in these very high risk patients, which may translate into a reduced risk of recurrent future events.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Atherosclerosis. Supplements
Atherosclerosis. Supplements 医学-外周血管病
CiteScore
4.80
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信